Parkinson’s research boosted with BioFocus/Michael J Fox Foundation collaboration
BioFocus has signed a collaboration agreement with The Michael J Fox Foundation for Parkinson’s Research, a not-for-profit organisation focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test.
As the world’s largest private funder of Parkinson’s research, The Michael J Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The foundation pursues its goals through a targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers.
In addition to funding over $240 million in research to date, the foundation has fundamentally altered the trajectory of progress towards a cure. Operating at the hub of worldwide Parkinson’s research, the foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.
NZ announces significant reforms to science sector
The reforms are intended to maximise the value of the $1.2 billion in government funding that...
Vaxxas to advance its microarray patches for COVID vaccination
Vaxxas will receive AU$3.2m from BARDA to accelerate work advancing its high-density microarray...
Global competition targets 'undruggable' cancer protein
A new global competition offering over US$500,000 in prizes aims to spur drug discovery...